Protein engineering company Aperiam Bio has officially emerged from stealth mode, revealing a successful seed funding round totaling $9 million. The funding round was led by OMX Ventures, with participation from Axial VC, KDT Ventures, and Civilization Ventures.
Proteins, essential building blocks of life, have traditionally presented challenges in engineering to enhance their functionality. Aperiam Bio aims to address this by utilizing a patented 3D computer vision algorithm, likened to “facial recognition for proteins,” to identify targeted improvements that make proteins more effective and durable.
The CEO of Aperiam Bio, Austin Cole, developed the structure-first algorithm over seven years at UT-Austin’s Ellington Lab of Molecular Biosciences. The algorithm enables scientists to streamline protein engineering, delivering shelf-stable proteins with enhanced applicability across various fields.
Aperiam Bio’s technology promises to revolutionize protein engineering, making it more efficient and applicable to a wide range of human challenges, from consumer products to pulmonary therapeutics. The seed funding will support further research and development of wholly-owned products, as well as the expansion of strategic partnerships to address various problems where pulmonary products offer solutions.
The successful seed round reflects the promising potential of Aperiam Bio’s approach to advancing protein engineering.
